For research use only. Not for therapeutic Use.
PD-L1-IN-2（Cat No.:I041188）is an investigational small molecule designed to inhibit the interaction between PD-L1 (programmed death-ligand 1) and its receptor PD-1, which plays a key role in immune evasion by tumors. By blocking this interaction, PD-L1-IN-2 aims to restore immune system activity and enhance the body’s ability to recognize and attack cancer cells. This approach is being explored for its potential in treating various cancers, including non-small cell lung cancer and melanoma. Ongoing clinical trials are assessing its safety, efficacy, and potential as a novel cancer immunotherapy.
| CAS Number | 2894733-91-4 |
| Synonyms | tert-butyl N-[3-[[5-[(3,4-dimethoxyphenyl)methyl]-4-[(4-methoxyphenyl)methyl]-1-methylimidazol-2-yl]carbamoyl]phenyl]carbamate |
| Molecular Formula | C33H38N4O6 |
| Purity | ≥95% |
| IUPAC Name | tert-butyl N-[3-[[5-[(3,4-dimethoxyphenyl)methyl]-4-[(4-methoxyphenyl)methyl]-1-methylimidazol-2-yl]carbamoyl]phenyl]carbamate |
| InChI | InChI=1S/C33H38N4O6/c1-33(2,3)43-32(39)34-24-10-8-9-23(20-24)30(38)36-31-35-26(17-21-11-14-25(40-5)15-12-21)27(37(31)4)18-22-13-16-28(41-6)29(19-22)42-7/h8-16,19-20H,17-18H2,1-7H3,(H,34,39)(H,35,36,38) |
| InChIKey | WCBUHIGCYKSAAG-UHFFFAOYSA-N |
| SMILES | CC(C)(C)OC(=O)NC1=CC=CC(=C1)C(=O)NC2=NC(=C(N2C)CC3=CC(=C(C=C3)OC)OC)CC4=CC=C(C=C4)OC |
